Entering text into the input field will update the search result below

NewLink Genetics' (NLNK) CEO Charles Link on Q4 2017 Results - Earnings Call Transcript

Mar. 01, 2018 9:58 PM ETLumos Pharma, Inc. (LUMO)
SA Transcripts profile picture
SA Transcripts

NewLink Genetics Corporation (NLNK) Q4 2017 Earnings Conference Call March 1, 2018 4:30 PM ET


John Henneman - Executive Vice President and Chief Financial Officer

Charles Link - Co-Founder, Chairman, Chief Executive Officer, Chief Scientific Officer

Eugene Kennedy - Chief Medical Officer


Jenny Huang - Bank of America Merrill Lynch

Stephen Willey - Stifel, Nicolaus & Company

Michael Ulz - Robert W. Baird

Peter Lawson - SunTrust Robinson Humphrey Inc

Biren Amin - Jefferies


Good afternoon, ladies and gentlemen, and welcome to the NewLink Genetics Fourth Quarter and Year-End 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Mr. Jack Henneman, Chief Financial Officer. Sir, you may begin.

John Henneman

Thank you. Good morning, and thank you for joining Dr. Charles Link, Chairman and Chief Executive Officer; Dr. Eugene Kennedy, Chief Medical Officer; and me, for the NewLink Genetics fourth quarter and year-end 2017 conference call.

After the market close, we issued a press release providing updates on our clinical development program for indoximod, NewLink’s IDO pathway inhibitor with a distinct mechanism of action, and fourth quarter and year-end financial results. Dr. Link will review our clinical and scientific priorities for 2018. Dr. Kennedy will review highlights for our clinical development programs, and I will wrap up with the fourth quarter and year-end 2017 financial results and updated cash guidance.

Certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.